Protein Design mit Rekordergebnis - 500 Beiträge pro Seite | Diskussion im Forum

[Nachrichten [wO]]

Das Biotechnologieunternehmen Protein Design Labs (Nasdaq: PDLI) meldete heute besser als erwartete Quartalsergebnisse. Der Gewinn für das 2. Quartal stieg um 85 Prozent an, die Analystenschätzungen wurden um 23 Prozent geschlagen.

Die Firma berichtet einen Profit von 5 Mio. US-Dollar oder 23 Cents je Aktie, nachdem im Vorjahresquartal noch 2,7 Mio. US-Dollar oder 14 Cents je Aktie verdient wurden. Die Erwartungen der Wall Street lagen bei 18 Cents je Aktie.

Die Umsätze stiegen um 150 Prozent auf 20,4 Mio. US-Dollar an. Das Umsatzwachstum wurde größtenteils durch eine erhöhte Nachfrage nach humanen monoklonalen Antikörpern getragen. Dabei kommt oft die Technologie von Protein Design Labs zum Einsatz. Die Umsätze beinhalten stark erhöhte Lizenzabgaben durch Synagis, ein Medikament zur Behandlung von Atemwegerkrankungen, das durch Medimmune vertrieben wird, das Brustkrebsmedikament Herceptin, vermarktet von Genentech, und Zenapax, zur Verhinderung von Organabstoßung bei Transplantationen, das von Hoffman-La Roche vertrieben wird.

Das Analystenhaus Dain Rauscher Wessels stufte das Biotechnologieunternehmen heut nach den guten Zhalen von „Neutral“ auf „Kaufen“ herauf.

Die Aktie gewinnt aktuell 14,1 Prozent auf 151-5/16 US-Dollar.

[poor_one]

SCHLECHTE NACHRICHT NACH NASDAQ SCHLUSS:


August 03, 2000


GKM analyst/ Protein Design Labs stock is overvalued

Bridge Information Systems, Inc. via NewsEdge Corporation : Boston--Aug. 2--According to Gerard Klauer Mattison analyst Ivonne Marondel, Protein Design Labs Inc.`s stock price is currently overvalued, although the company`s long term prospects look bright.
"I have a `neutral` on it, because at these levels, they`re overvalued," Marondel told BridgeNews Wednesday evening. However, Marondel also noted, "PDLI is the antibody company to be in on."
One of the biotech sector`s most expensive plays, Protein Design stock closed up 15 9/64 at 147 3/4 in active trading on Wednesday, in the wake of a better-than-expected earnings report issued Tuesday evening.
Earlier Wednesday, Marondel lowered her estimates for PDLI for fiscal 2000, 2001 and 2002 to reflect an anticipated decrease in royalty revenues over the next few quarters. Marondel also reiterated her neutral rating on the stock. (see story .18572)
On Tuesday, PDLI reported better than expected second quarter earnings of 25 cents per share on revenues on $20.4 million. First Call consensus had called for the company to post a profit of 18 cents per share. However, PDLI`s second quarter profit was due to increased royalty and licensing payments, many of which are seasonal. First Call analysts are expecting the company to post losses for the two remaining quarters this year and to post a loss for fiscal 2001 as well.
But analysts, Marondel included, also expect the company to begin turning the corner to sustained profitability by late 2002, and for the company to achieve sustained profitability by 2003. Marondel said that although she believes that the company`s royalty and licensing fees will provide a steady revenue stream for the company, PDLI still needs to roll out an in-house product in order to achieve sustained profits.
The company`s lead in-house drug, a treatment for leukemia called the Smart M195 Antibody, is currently in Phase III clinical testing. Marondel said that she anticipates the product to be on the market by early 2003. PDLI`s other products are licensed out to larger pharmaceutical or biotechnology companies, who then pay PDLI licensing fees or royalty percentages on product sales.
Meanwhile, Marondel said that she expects PDLI to post a loss for the third quarter 2000.
"I have them in the red for next quarter," she said. "They won`t be profitable for 2000."


[08-02-00 at 17:09 EDT